<DOC>
	<DOCNO>NCT01453101</DOCNO>
	<brief_summary>The hypothesis study regimen consist fludarabine , melphalan bortezomib improve progression free survival response rate compare historical control fludarabine melphalan alone .</brief_summary>
	<brief_title>Allogeneic Hematopoietic Stem Cell Transplantation Multiple Myeloma</brief_title>
	<detailed_description>Multiple myeloma second prevalent blood cancer ( 10 % ) non-hodgkin 's lymphoma . It represent approximately 1 % cancer 2 % cancer death . Although peak age onset multiple myeloma 70 year age , recent statistic indicate increase incidence earlier age onset . The historical control 2-year progression-free survival ( PFS ) assume 35 % . The propose therapy fludarabine , melphalan bortezomib expect improve PFS 20 % .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Diagnosis multiple myeloma Have suitable relate unrelated donor Age ≥18 &lt; 70 yr KPS ≥70 % Recovery complication previous therapy Diagnosis multiple myeloma Chemotherapy radiotherapy within 21 day initiate treatment study Prior doseintense therapy require HSC support within 56 day initiate treatment study Uncontrolled bacterial , viral , fungal parasitic infection Uncontrolled CNS metastasis Known amyloid deposition heart Organ dysfunction LVEF &lt; 40 % cardiac failure responsive therapy FVC , FEV1 , DLCO &lt; 50 % predict and/or receive supplementary continuous oxygen Evidence hepatic synthetic dysfunction , total bilirubin &gt; 2x AST &gt; 3x ULN Measured creatinine clearance &lt; 20 ml/min Sensory peripheral neuropathy grade 4 within 14 day enrollment Karnofsky score &lt; 70 % unless result bone disease directly cause myeloma Life expectancy limit another comorbid illness Diagnosed treat another malignancy within 3 year enrollment , exception complete resection basal cell carcinoma squamous cell carcinoma skin , situ malignancy , lowrisk prostate cancer curative therapy Female subject pregnant breastfeeding ( woman ) unwilling use acceptable birth control method ( men woman ) twelve month treatment . Confirmation subject pregnant must establish negative serum betahuman chorionic gonadotropin ( BhCG ) pregnancy test result obtain screening . Pregnancy test require postmenopausal surgically sterilize woman . Documented hypersensitivity fludarabine melphalan bortezomib , boron mannitol component formulation Patients unable unwilling provide consent Patient sustain platelet count &lt; 30 x 10 9/L within 14 day enrollment Patient sustain absolute neutrophil count &lt; 1.0 x10 9/L within 14 day enrollment Myocardial infarction within 6 month prior enrollment New York Heart Association ( NYHA ) Class III IV heart failure uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Prior study entry , ECG abnormality screen document investigator medically relevant Patient receive investigational drug 14 day enrollment Serious medical psychiatric illness likely interfere participation clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Transplant</keyword>
</DOC>